Role of monoclonal antibody drugs in the treatment of COVID-19 |
| |
Authors: | Claudio Ucciferri Jacopo Vecchiet Katia Falasca |
| |
Affiliation: | Claudio Ucciferri, Jacopo Vecchiet, Katia Falasca, Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Chieti 66100, ItalyClaudio Ucciferri, Department of Medicine and Health Sciences, University of Molise, Campobasso 66100, Italy |
| |
Abstract: | Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patients. Current studies on coronavirus disease 2019 (COVID-19) continue to highlight the urgent need for an effective therapy. Numerous therapeutic strategies have been used until now but, to date, there is no specific effective treatment for SARS-CoV-2 infection. Elevated inflammatory cytokines have been reported in patients with COVID-19. Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19. For these reason, numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19. The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation. |
| |
Keywords: | Tocilizumab Anakinra Canakinumab Ruxolitinib Clazakizumab Siltuximab Sarilumab Baricitinib Tofacitinib |
|
| 点击此处可从《World Journal of Clinical Cases》浏览原始摘要信息 |
|